Onzima Ventures Share Discussion Threads

[keya5000] 14/6/2016 15:53

Nigel just confirmed to me that todays news re 'talks late in 2016' refers only to the vaccines, other products are further advanced.

No I don't see a RTO, think they will list N4 on its own list with ONZ retaining the same equity interest that we have today.

Could be wrong and not fussed either way but I just cannot see it.

[keya5000] 14/6/2016 15:44

Just had it from the horse mouth, RNS today re talks is solely about the vaccines.

Fido rearrange these words up/sun/does/it/shine/shove/where/the/not.

Thank you.

Cut the market manipulation please. Its naughty.

[sja123] 14/6/2016 15:41

Are we looking at a possible RTO here as a way of getting a full listing for N4 Pharma? Anyone else thinking that way?

[keya5000] 14/6/2016 15:33

Fido,

This clearly outlines the 'talks' and why you are making a meal out of todays RNS in the wrong manner;

someuwin
14 Jun'16 - 15:10 - 112 of 112 1 0

So we currently have three near term partnering opportunities (that we are privy to)...

Their lead product is a novel patentable 'faster acting' version of Viagra which it is currently seeking to out-license to a large pharma co-development partner.

Then there is their unique single dose Hepatitis B vaccine which they have been working on for some time and could attract a big player any time.

And Today's RNS which is talking about their cancer vaccine & therapeutics vector technology which they will be looking to partner with later this year.

Plus an established drug co could well approach ONZ to reformulate one of their existing drugs.

With ONZ having identified 50 products (drugs & vaccines) there is no shortage of opportunities.

[fireball xl5] 14/6/2016 15:17

Fido, that is talks on this particular offering and they have always said later in 2016 for this. Get a grip!

[someuwin] 14/6/2016 15:10

So we currently have three near term partnering opportunities (that we are privy to)...

Their lead product is a novel patentable 'faster acting' version of Viagra which it is currently seeking to out-license to a large pharma co-development partner.

Then there is their unique single dose Hepatitis B vaccine which they have been working on for some time and could attract a big player any time.

And Today's RNS which is talking about their cancer vaccine & therapeutics vector technology which they will be looking to partner with later this year.

Plus an established drug co could well approach ONZ to reformulate one of their existing drugs.

With ONZ having identified 50 products (drugs & vaccines) there is no shortage of opportunities.

[fido] 14/6/2016 14:31

"talks have not even started"

I have been saying that for a while.
Now you have it in black & white from Nigels own mouth.

[fireball xl5] 14/6/2016 14:25

That may be the case. I unfortunately only look to the official updates and hopefully any forward looking statements are correct at the time of issue. They appear to be practicing what the are preaching and over time their credibility will be enhanced when these statements are brought to fruition.

[fido] 14/6/2016 14:11

Fireball XL5,
That much is correct but my point remains, the internet has been buzzing about a deal being signed when clearly that is not true because talks have not even started.

[fireball xl5] 14/6/2016 13:22

I'd like to think they are demonstrating that they are following announcements made in their RNS's. They said they would publish data and they have. They have said they intend to use this when beginning partner discussions later in the year. No doubt they will.

[fido] 14/6/2016 13:15

So RESEARCH & TESTING.
Just like I said. How long is that going to take.
No chance of a deal soon then.

[fireball xl5] 14/6/2016 13:14

The follow on today:

Publishing data.

"We now plan to embark on a more extensive research program at the University
of Queensland to determine the mode of action of transfection, and do
comparative testing on our particles transfection capability and toxicity
tests, further adding to our data package which we then intend to use to begin
potential partner discussions later in the year".

[fireball xl5] 14/6/2016 13:10

Yes, so am I and as previously stated:

Over the next few months we will continue to undertake experiments to demonstrate the capability of our vectors for both pDNA and mRNA, publishing the data when we can with a view to looking to engage with potential partners in the second half of 2016 to either work with their own particles or potentially acquire the rights to particles ourselves which we can then seek to take forward using these vectors.

And - what is it you don't understand?

[fido] 14/6/2016 13:06

keya5000,
You are so thick you don`t even understand what the RNS is talking about.
Well I do and this really is not big news.

[fido] 14/6/2016 13:02

Fireball XL5,
I am NOT talking a formulations, I am talking about talks beginning.
The internet has been full of talk about an impending deal being signed shortly when clearly that is NOT the case because the possible talks wont even start until later in the year and those talks could drag on for months or even years without any guarantee of success.

As I said, lies lies lies.

[keya5000] 14/6/2016 13:01

Fido.

Thats a direct reference to todays product/development and not the whole shooting match.

Please keep up.

[fireball xl5] 14/6/2016 12:57

Different applications Fido

in effect we are able to combine the onset advantages of Stendra and the long lasting advantages of Cialis into a new reformulation of sildenafil that will give the world's most popular drug for erectile dysfunction a new lease of life with strong long term patent protection.

This is the first example of how we plan to combine the patent skills from OPAL IP with the reformulation skills of N4 pharma and we will seek to repeat this with a number of other well-known drugs.

Our next step for this product is to open discussions with some of the leading formulation and pharmaceutical companies to partner us in bringing this new drug to market"

[fido] 14/6/2016 12:50

"adding to our data package which we then intend to use to begin
potential partner discussions later in the year".

BEGIN discussions later in the year?????

What ever happened to "we are expecting a deal to be signed shortly"

Lies lies and more lies.

[keya5000] 14/6/2016 12:09

Very positive RNS, perhaps too technical for the layman to understand.

[sophisticatedtrader] 14/6/2016 12:04

I like the bit saying 'ticks two key initial boxes...that potential partner companies would want to see!'

[someuwin] 14/6/2016 11:50

All sounds very positive to me - but a bit over my head.

I have emailed Nigel for a better understanding.

[someuwin] 14/6/2016 11:30

14/06/2016 10:17am

UK Regulatory (RNS & others)


TIDMONZ

Onzima Ventures PLC
("Onzima" or the "Company")

Vaccine data release by N4 Pharma

Onzima is pleased to announce that N4 Pharma Limited ("N4 Pharma"), its
49%-owned investee company, has made available on its website (
www.n4pharma.co.uk) initial research findings by University of Queensland on
its vaccine technology concerning its suitability as a vector to help deliver
pDNA and mRNA molecules for cancer vaccines and therapeutics. Particularly it
has made available data concerning particle size optimisation for its silica
nano particles and the ability of the particles to protect nucleic acid from
attack.

In addition, as the manufacture process required to make the particle for pDNA
and mRHA use is substantially different to that for its original nuvac®
particle for sub unit vaccines, N4 Pharma has decided to rebrand this approach
as nuvecT to provide further differentiation and clarity to its portfolio.

N4 Pharma CEO Nigel Theobald commented:

"A good delivery vector must be able to help deliver the vaccine molecule
through the cell wall and into the cell where it can "do its thing" (this is
known as transfection). Our work shows we can vary our nanoparticle size to
optimise this effect, demonstrating the versatility of our vector.

"A good vector for pDNA and mRNA delivery must also be able to protect the
nucleic acid from attack by nuclease once it is in the body. Our data also
shows how well our nanoparticle does this.

"These are two key elements biotech companies look for in novel delivery
vectors so this is good news for N4 as this ticks two key initial boxes
potential partner companies will want to see.

"We now plan to embark on a more extensive research program at the University
of Queensland to determine the mode of action of transfection, and do
comparative testing on our particles transfection capability and toxicity
tests, further adding to our data package which we then intend to use to begin
potential partner discussions later in the year".

[phil1969] 14/6/2016 11:26

Sometouwin, yes your formula is correct. But how does that relate to ONZ?Demand is mediocre and supply is plentiful. Even an RNS can't get this moving.

[someuwin] 14/6/2016 09:54

Large demand + limited supply = big share price rise.